You can buy or sell PDL BioPharma and other stocks, options, ETFs, and crypto commission-free!
PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. Read More The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.
Incline Village, Nevada
52 Week High
52 Week Low
Yahoo FinanceMay 12
Were Hedge Funds Right About Piling Into PDL BioPharma Inc.?
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after...
Seeking AlphaMay 9
PDL BioPharma beats by $0.01, beats on revenue
PDL BioPharma (NASDAQ:PDLI): Q1 Non-GAAP EPS of $0.09 beats by $0.01 ; GAAP EPS of $0.05 misses by $0.03 . Revenue of $38.9M (+1.0% Y/Y) beats by $4.22M . Press Release...
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?
Investor focus will be on PDL BioPharma, Inc.'s PDLI ability to acquire new income-generating assets for a recurrent revenue uptick, when the company reports first-quarter 2019 earnings in the days ahead. The company's surprise track record has been impressive so far, having delivered an earnings beat in each of the trailing four quarters, the average being 38.39%. In the las t report ed quarter, PDL BioPharma came up with a positive surprise of 25.00%. Shares of PDL BioPharma have gained10.3% so far this...
Expected Aug 7, After Hours